⚖
Compare Funds
See how two funds stack up side by side, real returns, risk, cost and portfolio overlap.
VS
Key Metrics Comparison
| Metric | Arthaya Equity Long Short Fund - Growth - Direct Plan | HDFC Pharma and Healthcare Fund - Growth - Direct Plan |
|---|---|---|
| Snapshot | ||
| AMC | Arthaya SIF | HDFC MF |
| Category | Equity - Long-Short Fund | Equity - Sectoral Fund - Pharma & Health Care |
| NAV | ₹9.74 (30 Oct 2026) | ₹21.95 (30 Oct 2026) |
| Rating | ★★★ | ★★★★★ |
| Benchmark | NIFTY 200 - TRI | BSE Health Care - TRI |
| Fund Manager | Rajesh Aynor | Nikhil Mathur |
| Inception | 25 May 2026 | 04 Oct 2023 |
| Returns | ||
| 1Y | — | 22.64% |
| 3Y | — | 30.41% |
| 5Y | — | — |
| Since Inception | -2.40% | 29.15% |
| Risk | ||
| 5.12 | 14.07 | |
| 0.41 | 0.59 | |
| -2.97 | 1.59 | |
| -9.89 | 21.67 | |
| -3.78 | 3.48 | |
| -3.17% | -9.23% | |
| Costs | ||
| Expense Ratio | 4.35% | 1.03% |
| Exit Load | 1% on or before 1Y, Nil after 1Y | 1% on or before 30D, Nil after 30D |
| Min SIP | ₹10,000 | ₹100 |
| Min Lumpsum | ₹10,00,000 | ₹100 |
| Lock-in | None | None |
Min SIP is reported per fund, not per plan, every plan of a fund shares the same figure.
Portfolio Overlap
Arthaya SIF97%
HDFC MF97%
2.6%Only 2.6% of holdings by weight are common between Arthaya SIF and HDFC MF, based on each fund's top 20 disclosed holdings, not the full portfolio.
Common holdingArthaya SIFHDFC MF
Divi's Laboratories Ltd.2.63%9.39%
Category context: Equity vs Equity. Open the full Screener →